Correspondence: Professeur A Perdriger Service de rhumatologie, CHU de rennes, Hôpital sud, 16 boulevard de Bulgarie, 35056 rennes Cedex, France Tel +33 (02) 99 26 71 40 Fax +33 (02) 99 26 71 90 Email [email protected] Abstract: Infliximab was the first monoclonal antibody to human necrosis factor alpha (TNFα) developed for treating rheumatoid arthritis (RA). This chimeric antibody ...

Inflammatory bowel disease (IBD), comprised primarily of Crohn’s disease (CD) and ulcerative colitis (UC), is estimated to affect approximately 1 million individuals in the United States alone, with approximately 30,000 new cases diagnosed annually.1 A hallmark of this disease is chronic inflammation of the intestinal mucosa, which results in part from production of the tumor necrosis factor–α ...

OBJECTIVE To analyse the use of health care resources and the associated costs in patients with rheumatoid arthritis (RA) treated with three biological disease-modifying anti-rheumatic drugs (bDMARDs): etanercept, infliximab and adalimumab. METHOD DESIGN observational, retrospective, multicentre study. Length of study: 6 months. TARGET POPULATION patients with RA, who have been undergoin...

PURPOSE To describe a patient with Behçet's disease and anterior uveitis, which was not cured by local and systemic corticosteroid treatments, who underwent trabeculotomy one week after infliximab administration. METHODS The patient received preoperative antibiotic therapy followed by trabeculotomy one week after infliximab administration. We observed ocular findings before and after surgery....

BACKGROUND Infliximab, a TNF-alpha blocking agent, is an upcoming therapeutic option for cases of refractory sarcoidosis. In pulmonary sarcoidosis, changes imaged by 18F-FDG-PET during infliximab treatment in sarcoidosis patients correlate with signs of clinical improvement. DESIGN Case-report. RESULTS AND CONCLUSIONS A patient with severe earlobe sarcoidosis, treated with infliximab, is pr...

Crohn's disease is characterized by inflammation of the mucosal lining of the gastrointestinal tract. Infliximab is a tumor necrosis factor-α inhibitor that has been associated with increased remission and decreased disease flare-ups. Biological agents such as infliximab have been associated with adverse events. We present a rare case of cardiac tamponade caused by infliximab treatment for Croh...

BACKGROUND Infliximab, a TNF-α inhibitor, is a potent anti-inflammatory drug in the treatment of inflammatory bowel diseases. Recent studies have investigated the effect of infliximab treatment on postoperative complications such as anastomotic leakage, however, with conflicting results and conclusions. The purpose of this study was to investigate whether a single dose infliximab has an adverse...

OBJECTIVE To evaluate the efficacy and toxicity of infliximab for the treatment of fistulizing Crohn's disease. METHODS Consecutive patients with fistulizing Crohn's disease receiving infliximab were prospectively enrolled. Partial response was defined as a reduction of 50% or more from base-line in the number of draining fistulae. Complete response was defined as the closure of all fistulae....

BACKGROUND & AIMS Crohn's disease commonly recurs after intestinal resection. We evaluated whether the administration of infliximab after resective intestinal surgery for Crohn's disease reduces postoperative recurrence. METHODS We randomly assigned 24 patients with Crohn's disease who had undergone ileocolonic resection to receive intravenous infliximab (5 mg/kg), administered within 4 weeks...

BACKGROUND/AIMS Infliximab has been approved for the treatment of chronic plaque psoriasis for only a few years. As physicians gain confidence in initiating and maintaining this therapy, guidance on the management of patients beyond several months or years is needed. To date, there is little or no information about the long-term management in clinical trials or guidelines. METHODS Here we rep...